Practitioner's Guide
How to Source Exosomes for Your Clinic: A Practitioner's Guide
The exosome supply market is uneven. Not all products are equally characterized, and not all COAs tell the full story. This guide covers what particle count actually means, what characterization data to require, how to read an exosome COA, and the red flags that signal a supplier you should avoid.
Written by Benn Bluestein-Veyra, M.Sc. Organic Chemistry — Founder, ExaVeyra Sciences
The ExaBlog
New: The science behind exosomes in aesthetic medicine — clinical trials, MSC sourcing, and honest caveats.
What You're Actually Buying
Exosomes are nano-sized extracellular vesicles — 30 to 150 nanometers in diameter — secreted by cells as a primary mechanism of intercellular communication. When derived from mesenchymal stem cells (MSCs), they carry a cargo of growth factors, cytokines, mRNA, microRNA, and signaling proteins that instruct recipient cells to reduce inflammation, proliferate, and regenerate tissue.
But "exosomes" is also a loosely applied marketing term. In the supply market, products labeled as exosomes range from rigorously characterized MSC-derived preparations with full NTA data and tetraspanin marker confirmation, to poorly defined cell culture supernatants with minimal quality control. The difference between these products is significant — clinically and commercially — and a COA alone does not tell the whole story.
Understanding what questions to ask, what data to require, and what characterization standards define a quality exosome preparation is the foundation of responsible sourcing. This guide gives you that framework.
Understanding Particle Count
Particle count — reported as particles per mL or per vial — is the most commonly cited quality metric for exosome products. Vials typically range from 50 billion to 700 billion particles, with higher counts commanding premium pricing. But particle count in isolation is a marketing number, not a quality metric.
What matters alongside particle count is how it was measured, what the size distribution looks like, and what fraction of those particles are genuine exosomes rather than larger microvesicles, apoptotic bodies, or protein aggregates. The gold-standard measurement method is Nanoparticle Tracking Analysis (NTA) — a technique that tracks individual particles under laser illumination and reports both concentration and size distribution simultaneously.
A quality exosome preparation should show an NTA size distribution with a predominant peak between 50 and 150 nanometers. Preparations with broad distributions, secondary peaks above 200nm, or NTA data that has not been provided at all should prompt follow-up questions before ordering.
NTA — What to Look For
- Predominant size peak: 50–150nm
- Narrow size distribution (low polydispersity index)
- Concentration reported in particles/mL with methodology noted
- Mode and mean size both reported
- NTA instrument model and settings disclosed
Characterization Standards — What Defines a Genuine Exosome
The International Society for Extracellular Vesicles (ISEV) publishes Minimal Information for Studies of Extracellular Vesicles (MISEV) guidelines that define the characterization standards for rigorous exosome research. While clinical suppliers are not required to follow MISEV, it provides the scientific community's consensus on what constitutes adequate characterization.
The most clinically relevant characterization markers are the tetraspanins — CD63, CD9, and CD81. These transmembrane proteins are highly enriched on the surface of exosomes relative to other extracellular vesicles and cellular components. Their presence, confirmed by Western blot or flow cytometry, provides molecular evidence that the preparation contains genuine exosomes, not just cell culture supernatant debris.
A supplier that cannot provide tetraspanin marker data is not selling characterized exosomes. They may be selling a vesicle preparation, a conditioned medium concentrate, or something else entirely — but without CD63/CD9/CD81 confirmation, "exosome" is an unverified claim.
CD63
Late endosomal marker. Primary tetraspanin used to confirm exosomal origin. High enrichment on genuine exosomes.
CD9
Cell surface tetraspanin enriched on exosomes. Important for exosome biogenesis and fusion. Used alongside CD63.
CD81
Tetraspanin involved in membrane organization. Third primary exosome marker. Together with CD63/CD9, confirms identity.
Exosome COA Checklist — What to Require
Before placing your first order with any exosome supplier, request a sample COA and verify it includes the following. Critical items are non-negotiable for clinical sourcing.
Red Flags — When to Walk Away
The following are warning signs that a supplier's product quality or documentation standards are insufficient for clinical sourcing.
Liquid vs Lyophilized — Choosing the Right Format
Exosomes are supplied in two primary formats: liquid (aqueous suspension) and lyophilized (freeze-dried). The format choice has significant practical implications for shipping, storage, and clinic inventory management.
Liquid exosomes require cold-chain shipping at 2–8°C and have a shorter post-receipt shelf life — typically days to weeks depending on formulation. They are ready to use immediately upon receipt but demand refrigeration and timely use. Cold-chain failures during shipping — broken ice packs, temperature excursions — can degrade biological activity without visible changes to the product.
Lyophilized exosomes are freeze-dried under controlled conditions that preserve particle integrity and biological cargo. They ship ambient, have shelf lives of 2–3 years at appropriate storage conditions, and reconstitute with sterile water for injection before use. For most clinic settings, lyophilized formats are substantially more practical for inventory management and reduce the risk of cold-chain compromise.
How ExaVeyra Sciences Evaluates Exosome Suppliers
At ExaVeyra Sciences, every exosome product in our catalog is evaluated by our founder — an M.Sc. organic chemist with expertise in analytical chemistry, synthetic chemistry, and biochemistry. We apply the same analytical rigor to supplier evaluation that we applied in the laboratory: methodology matters as much as the reported result.
Our evaluation process covers NTA data and instrument methodology, tetraspanin marker characterization by Western blot or flow cytometry, sterility and endotoxin testing methodology, manufacturing facility registration and cGMP compliance documentation, cold-chain handling protocols, and lot-to-lot consistency data. We do not onboard suppliers who cannot provide complete characterization documentation.
For our wholesale partners, we provide lot numbers and COA documentation with every order and can provide the underlying characterization data on request. Our supply chain is designed for practitioner confidence — not just product delivery.
Exosome Sourcing FAQ
- What particle count should I look for when sourcing exosomes?
- Particle count is reported as particles per mL or per vial, measured by Nanoparticle Tracking Analysis (NTA). For clinical use, vials typically range from 50 billion to 700 billion particles. Higher counts are not always better — the ratio of exosomes to other extracellular vesicles, the size distribution, and the biological cargo matter as much as raw count. Always ask for NTA data, not just a reported number.
- What characterization data should a quality exosome COA include?
- A quality exosome COA should include: NTA particle count and size distribution (typically 30–150nm peak), tetraspanin marker expression (CD63, CD9, CD81) confirming exosome identity, sterility testing results, endotoxin (LAL) test results, mycoplasma testing, and lot number with manufacturing date. Absence of any of these is a red flag.
- What is NTA and why does it matter for exosome quality?
- Nanoparticle Tracking Analysis (NTA) is the gold-standard method for characterizing exosome preparations. It measures particle concentration and size distribution in real time by tracking individual particle Brownian motion under laser illumination. NTA data should show a predominant peak between 50–150nm. Preparations with broad size distributions or peaks outside this range may contain significant contamination from larger vesicles or cellular debris.
- What are the tetraspanin markers and why do they confirm exosome identity?
- CD63, CD9, and CD81 are tetraspanin proteins highly enriched on the surface of exosomes. Their presence, confirmed by Western blot or flow cytometry, verifies that the preparation contains genuine exosomes rather than just cell debris or non-vesicular protein aggregates. A supplier that cannot provide tetraspanin marker data is not selling characterized exosomes.
- What is the difference between liquid and lyophilized exosomes for clinic use?
- Liquid exosomes require cold-chain shipping (2–8°C) and have a shorter shelf life after receipt. Lyophilized (freeze-dried) exosomes ship ambient, have a 2–3 year shelf life, and reconstitute with sterile water before use. For clinic inventory management, lyophilized formats are significantly more practical. Both formats can maintain equivalent biological activity when properly manufactured.
- What red flags should I watch for when evaluating an exosome supplier?
- Red flags include: no NTA data (just a reported particle count), no tetraspanin marker confirmation, no sterility or endotoxin test data, no lot numbers, inability to provide COA on request, claims of 'stem cell exosomes' without specifying cell source, no information about manufacturing facility registration, and pricing that seems too good to be true relative to verified cGMP suppliers.
- Are exosomes regulated by the FDA?
- MSC-derived exosomes occupy a complex regulatory space. They are generally classified as biological products under FDA jurisdiction rather than as compounded drugs. The FDA has issued guidance indicating that many exosome products intended for clinical use would require IND (Investigational New Drug) applications or BLA (Biologics License Application) pathways. Clinics should work with suppliers who provide full manufacturing documentation and stay current on FDA guidance in this rapidly evolving area.
- How does ExaVeyra Sciences verify exosome quality before supplying to clinics?
- Our founder — an M.Sc. organic chemist with a background in analytical chemistry — reviews manufacturing documentation, NTA data, tetraspanin marker characterization, sterility and endotoxin testing, and stability data for every exosome product in our catalog. We evaluate the analytical methodology behind the COA, not just the summary document. Products that cannot provide complete characterization data do not enter our supply chain.
Related Resources
Exosome Product Catalog
Browse our MSC-derived exosome lineup — liquid and lyophilized, 50B to 700B particles.
Read →503A vs 503B Guide
Understand compounding regulatory frameworks and which applies to your clinic sourcing.
Read →Exosomes & Aesthetic Medicine
Peer-reviewed deep dive: MSC sourcing, 292 registered clinical trials, and the science behind the buzz.
Read →Wholesale Partner Program
Apply for NPI-verified access to our full exosome catalog with COA and lot tracking.
Read →Source Exosomes You Can Trust
ExaVeyra supplies licensed clinics with cGMP, NTA-characterized, tetraspanin-confirmed MSC-derived exosomes — reviewed by an M.Sc. organic chemist. Full COA and lot tracking on every order.